Artiva Biotherapeutics, Inc. (ARTV)
(Delayed Data from NSDQ)
$2.76 USD
+0.12 (4.55%)
Updated Aug 8, 2025 03:59 PM ET
After-Market: $2.76 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Artiva Biotherapeutics, Inc.'s return on equity, or ROE, is -42.60% compared to the ROE of the Medical - Biomedical and Genetics industry of -61.64%. While this shows that ARTV has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ARTV 2.76 +0.12(4.55%)
Will ARTV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARTV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARTV
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
ARTV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ARTV
Artiva Biotherapeutics GAAP EPS of -$0.87 misses by $0.06
Artiva Biotherapeutics files $300M mixed securities shelf
12 Health Care Stocks Moving In Wednesday's After-Market Session
Artiva Biotherapeutics Approves Equity Plan Amendment
Promising Advancements and Financial Strength Position Artiva Biotherapeutics for Significant Upside